EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats

Cyril Thouverey, Isabelle Badoud, Patrick Ammann

Calcified Tissue International · 28.07.2026 · 117 (1)

DOI: 10.1007/s00223-026-01575-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Calcified Tissue International, online erschienen am 28.07.2026. Verfasst von Cyril Thouverey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Service of Bone Diseases, Department of Medicine, University Hospital of Geneva, 64 Avenue de la Roseraie, 1205, Geneva, Switzerland. Cyril.Thouverey…. Hauptthemen laut MEDLINE: Strontium, Parathyroid Hormone, Bone and Bones, Teriparatide. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fondation pour la Recherche sur l'Ostéoporose et les Maladies Osseuses.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To optimize osteoporosis therapy with the parathyroid hormone fragment teriparatide (PTH1-34), we sought to determine whether strontium (Sr) could potentiate the bone anabolic action of intermittent PTH1-34 in ovariectomized rats. Female rats were either Sham-operated or ovariectomized (Ovx) at 6 months of age. Eight weeks after surgery, Ovx rats received either vehicle solutions, 625 mg/kg/day Sr (5 days per week), 8 µg/kg/day PTH1-34 (5 days per week), or the combined treatments for 8 weeks. PTH1-34 reversed Ovx-induced deterioration of trabecular microarchitecture, apparent volumetric bone mineral density (vBMD), and strength, whereas Sr alone increased tissue-level vBMD without significantly affecting trabecular bone mass. Co-treatment with Sr and PTH1-34 further increased trabecular thickness (+ 8.9% vs. PTH1-34 alone), apparent and tissue-level vBMD (+ 9.6% and 6.7% vs. PTH1-34 alone), bone material properties (maximum force, + 18.2% vs. PTH1-34 alone; working energy, + 17% vs. PTH1-34 alone), and trabecular bone strength compared with PTH1-34 alone. In cortical bone, PTH1-34 increased bone volume, cortical thickness, and apparent vBMD, while co-treatment further enhanced cortical thickness (+ 7.2% vs. PTH1-34 alone) and apparent vBMD (+ 7% vs. PTH1-34 alone), maintained the Sr-induced increase in tissue-level vBMD, and significantly improved bone strength. In primary osteoblast cultures, Sr and PTH1-34, administered either alone or in combination, increased Rankl and decreased Opg expression, consistent with the elevated urinary levels of the bone resorption marker deoxypyridinoline in vivo. Sr or PTH1-34 alone stimulated Igf1 and Alpl expression, whereas co-stimulation further enhanced these osteogenic markers. In conclusion, combining Sr with PTH1-34 integrates the osteoanabolic effects of PTH1-34 on bone mass with the mineral-level effects of Sr on bone material properties, leading to synergistic stimulation of bone formation and superior improvements in bone quality and strength.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrontiumParathyroid HormoneBone and BonesTeriparatideOsteoporosisBone Density Conservation AgentsAnimalsFemaleOvariectomyBone DensityRatsRats, Sprague-DawleyAnabolic Agents

Stichwörter der Autor:innen

Bone anabolismCombined therapyOsteoporosisParathyroid hormoneStrontium

Substanzen

StrontiumParathyroid HormoneTeriparatideBone Density Conservation AgentsAnabolic Agents

Autor:innen und Institutionen

  • Service of Bone Diseases, Department of Medicine, University Hospital of Geneva, 64 Avenue de la Roseraie, 1205, Geneva, Switzerland. Cyril.Thouverey@unige.ch.
  • Service of Bone Diseases, Department of Medicine, University Hospital of Geneva, 64 Avenue de la Roseraie, 1205, Geneva, Switzerland.

Förderung

  • Servier
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Fondation pour la Recherche sur l'Ostéoporose et les Maladies Osseuses
  • American Society for Bone and Mineral Research
  • Fondation pour la Recherche sur l’Ostéoporose et les Maladies Osseuses

Zitieren

APA

Thouverey, C., Badoud, I., & Ammann, P. (2026). Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01575-x

Vancouver

Thouverey C, Badoud I, Ammann P. Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01575-x

BibTeX
@article{Thouverey2026,
  author = {Thouverey, Cyril and Badoud, Isabelle and Ammann, Patrick},
  title = {Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats},
  journal = {Calcified Tissue International},
  year = {2026},
  volume = {117},
  number = {1},
  doi = {10.1007/s00223-026-01575-x}
}
Kostenlos starten →